Kymera Therapeutics

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiated dosing of healthy volunteers in the Multiple Ascending Dose portion of Phase 1 trial of KT-474 Expect Investigational